Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Syndax Pharmaceuticals, Inc./ 10-Q

Quarterly Report · 10-Q

Syndax Pharmaceuticals, Inc.

SNDXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 4, 2026Accepted Aug 4, 2026, 4:04 PM EDTCIK 1395937Accession 0001193125-26-332750
View company →Permanent SEC source ↗
Share

Company context

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is

Current securities

SNDXNASDAQ · EQUITY · Current

Recent company filings

  1. 4 filingOct 30, 2026
  2. 144 filingOct 29, 2026
  3. Results of Operations and Financial ConditionAug 4, 2026
  4. Other EventsJul 14, 2026
  5. 144 filingJul 8, 2026

Registered securities in this filing

Syndax Pharmaceuticals, Inc. · 10-Q · Filed 2026-08-04

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
SNDX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: C_8c49c18c-f675-46bf-9d09-14aff3a2f286

Dimensions: Not supplied

Accession 000119312526332750 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.